본문 바로가기
KERD
논문KCI 등재

Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad

Zhang Junfeng|Ge Yongtong|Cheng Dalei|Jia Qingzhi|Xiong Huabao
대한면역학회 (The Korean Association of Immunologists)|2021.06|Immune Network|제21권 제3호|pp. 1-22|DOI 10.4110/in.2021.21.e21

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

ImmunosuppressionNeuroinflammatoryMyeloid-derived suppressor cellsTumor disease

초록

Myeloid-derived suppressor cells (MDSCs) have strong immunosuppressive activity and are morphologically similar to conventional monocytes and granulocytes. The development and classification of these cells have, however, been controversial. The activation network of MDSCs is relatively complex, and their mechanism of action is poorly understood, creating an avenue for further research. In recent years, MDSCs have been found to play an important role in immune regulation and in effectively inhibiting the activity of effector lymphocytes. Under certain conditions, particularly in the case of tissue damage or inflammation, MDSCs play a leading role in the immune response of the central nervous system. In cancer, however, this can lead to tumor immune evasion and the development of related diseases. Under cancerous conditions, tumors often alter bone marrow formation, thus affecting progenitor cell differentiation, and ultimately, MDSC accumulation. MDSCs are important contributors to tumor progression and play a key role in promoting tumor growth and metastasis, and even reduce the efficacy of immunotherapy. Currently, a number of studies have demonstrated that MDSCs play a key regulatory role in many clinical diseases. In light of these studies, this review discusses the origin of MDSCs, the mechanisms underlying their activation, their role in a variety of clinical diseases, and their function in immune response regulation.

Abstract

Myeloid-derived suppressor cells (MDSCs) have strong immunosuppressive activity and are morphologically similar to conventional monocytes and granulocytes. The development and classification of these cells have, however, been controversial. The activation network of MDSCs is relatively complex, and their mechanism of action is poorly understood, creating an avenue for further research. In recent years, MDSCs have been found to play an important role in immune regulation and in effectively inhibiting the activity of effector lymphocytes. Under certain conditions, particularly in the case of tissue damage or inflammation, MDSCs play a leading role in the immune response of the central nervous system. In cancer, however, this can lead to tumor immune evasion and the development of related diseases. Under cancerous conditions, tumors often alter bone marrow formation, thus affecting progenitor cell differentiation, and ultimately, MDSC accumulation. MDSCs are important contributors to tumor progression and play a key role in promoting tumor growth and metastasis, and even reduce the efficacy of immunotherapy. Currently, a number of studies have demonstrated that MDSCs play a key regulatory role in many clinical diseases. In light of these studies, this review discusses the origin of MDSCs, the mechanisms underlying their activation, their role in a variety of clinical diseases, and their function in immune response regulation.

참고문헌 (149)

  1. Bruger AM, "How to measure the immunosuppressive activity of MDSC : assays, problems and potential solutions", Cancer Immunol Immunother, 68, pp.631~644 (2019)
  2. Llitjos JF, "Sepsis-induced expansion of granulocytic myeloid-derived suppressor cells promotes tumour growth through Toll-like receptor 4", J Pathol, 239, pp.473~483 (2016)
  3. Luker AJ, "The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer", BMC Immunol, 21, pp.8~ (2020)
  4. Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)
  5. Poschke I, "On the armament and appearances of human myeloid-derived suppressor cells", Clin Immunol, 144, pp.250~268 (2012)
  6. Cassetta L, "Deciphering myeloid-derived suppressor cells : isolation and markers in humans, mice and nonhuman primates", Cancer Immunol Immunother, 68, pp.687~697 (2019)
  7. Bruderek K, "Immunophenotyping of circulating myeloid-derived suppressor cells(MDSC)in the peripheral blood of cancer patients", Mol Biol, 2236, pp.1~7 (2021)
  8. Singh A, "In vitro generation of human neutrophilic myeloid-derived suppressor cells", Methods Mol Biol, 2236, pp.77~83 (2021)
  9. Hanson EM, "Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells", J Immunol, 183, pp.937~944 (2009)
  10. Shi H, "Arctigenin ameliorates inflammation by regulating accumulation and functional activity of MDSCs in endotoxin shock", Inflammation, 41, pp.2090~2100 (2018)
  11. Gao Y, "Lnc-C", EBPβ negatively regulates the suppressive function of myeloid-derived suppressor cells, 2018, pp.6, 1352~1363
  12. Pinton L, "Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression", Oncotarget, 7, pp.1168~1184 (2016)
  13. Bird L, "MDSC metabolite stuns T cells", Nat Rev Immunol, 20, pp.352~353 (2020)
  14. Xu Z, "MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma", FEBS J, 284, pp.2410~2424 (2017)
  15. Özkan B, "Immunomodulatory function of myeloid-derived suppressor cells during B cellmediated immune responses", Int J Mol Sci, 19, pp.1468~ (2018)
  16. Aarts CEM, "Different MDSC activity of G-CSF", dexamethasone mobilized neutrophils: benefits to the patient?, 2020, pp.10, 1110~
  17. Leiber A, "Neonatal myeloid derived suppressor cells show reduced apoptosis and immunosuppressive activity upon infection with Escherichia coli", Eur J Immunol, 47, pp.1009~1021 (2017)
  18. Groth C, "Immunosuppression mediated by myeloid-derived suppressor cells(MDSCs)during tumour progression", Br J Cancer, 120, pp.16~25 (2019)
  19. Aarts CEM, "Neutrophils as myeloid-derived suppressor cells", Eur J Clin Invest, 48(Suppl 2), pp.e12989~ (2018)
  20. Salminen A, "Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells(MDSC) : Impact on cancer and age-related chronic inflammatory disorders", Int Immunopharmacol, 61, pp.231~240 (2018)
  21. Thakuri BKC, "HCV-associated exosomes upregulate RUNXOR and RUNX1 expressions to promote MDSC expansion and suppressive functions through STAT3-miR124 axis", Cells, 9, pp.2715~ (2020)
  22. Bronte V, "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards", Nat Commun, 7, pp.12150~ (2016)
  23. Tcyganov E, "Plasticity of myeloid-derived suppressor cells in cancer", Curr Opin Immunol, 51, pp.76~82 (2018)
  24. Koehn BH, "GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells", Blood, 126, pp.1621~1628 (2015)
  25. Mandruzzato S, "Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry : results from an interim study", Cancer Immunol Immunother, 65, pp.161~169 (2016)
  26. Elliott LA, "Human tumor-infiltrating myeloid cells : phenotypic and functional diversity", Front Immunol, 8, pp.86~ (2017)
  27. Safarzadeh E, "Myeloid-derived suppressor cells : important contributors to tumor progression and metastasis", J Cell Physiol, 233, pp.3024~3036 (2018)
  28. Cassetta L, "Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation", J Immunother Cancer, 8, pp.e001223~ (2020)
  29. Dumitru CA, "Neutrophils and granulocytic myeloid-derived suppressor cells : immunophenotyping, cell biology and clinical relevance in human oncology", Cancer Immunol Immunother, 61, pp.1155~1167 (2012)
  30. Heuvers ME, "Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients", Lung Cancer, 81, pp.468~474 (2013)
  31. Huang A, "Increased CD14(+)HLA-DR(-", low)myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients, 2013, pp.62, 1439~1451
  32. Tian T, "Increased circulating CD14(+)HLA-DR-", low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer, 2015, pp.15, 425~432
  33. de Goeje PL, "Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer", OncoImmunology, 4, pp.e1014242~ (2015)
  34. Li J, "CD39", CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer, 2017, pp.6, e1320011~
  35. Vetsika EK, "A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic", predictive factor in untreated non-small lung cancer patients, 2014, pp.2014, 659294~
  36. Limagne E, "Tim-3", galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients, 2019, pp.8, e1564505~
  37. Passaro A, "Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy", Clin Transl Oncol, 22, pp.603~611 (2020)
  38. Veglia F, "Myeloid-derived suppressor cells coming of age", Nat Immunol, 19, pp.108~119 (2018)
  39. Condamine T, "Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients", Sci Immunol, 1, pp.aaf8943~ (2016)
  40. Rébé C, "STAT3 activation : a key factor in tumor immunoescape", JAKSTAT, 2, pp.e23010~ (2013)
  41. Marigo I, "Tumor-induced tolerance and immune suppression depend on the C", EBPbeta transcription factor, 2010, pp.32, 790~802
  42. Brajer-Luftmann B, "Molecules of damage-associated patterns in bronchoalveolar lavage fluid and serum in chronic obstructive pulmonary disease", Adv Exp Med Biol, 1113, pp.27~35 (2019)
  43. Mei Y, "Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q)MDS", Leukemia, 32, pp.1023~1033 (2018)
  44. Nakamura K, "Myeloid immunosuppression and immune checkpoints in the tumor microenvironment", Cell Mol Immunol, 17, pp.1~12 (2020)
  45. Koehn BH, "Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD", Blood, 134, pp.1670~1682 (2019)
  46. Salminen A, "The role of myeloid-derived suppressor cells(MDSC)in the inflammaging process", Ageing Res Rev, 48, pp.1~10 (2018)
  47. Condamine T, "Transcriptional regulation of myeloid-derived suppressor cells", J Leukoc Biol, 98, pp.913~922 (2015)
  48. Condamine T, "Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function", Trends Immunol, 32, pp.19~25 (2011)
  49. Chalmin F, "Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells", J Clin Invest, 120, pp.457~471 (2010)
  50. Chaib M, "Friend or foe? Recent strategies to target myeloid cells in cancer", Front Cell Dev Biol, 8, pp.351~ (2020)
  51. Kondratova M, "A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures", Nat Commun, 10, pp.4808~ (2019)
  52. Dai H, "Connections between metabolism and epigenetic modification in MDSCs", Int J Mol Sci, 21, pp.7356~ (2020)
  53. Coffelt SB, "Neutrophils in cancer : neutral no more", Nat Rev Cancer, 16, pp.431~446 (2016)
  54. Treffers LW, "Neutrophils in cancer", Immunol Rev, 273, pp.312~328 (2016)
  55. Xie Z, "Valproic acid attenuates immunosuppressive function of myeloidderived suppressor cells", J Pharmacol Sci, 137, pp.359~365 (2018)
  56. Bobetsis YA, "Exploring the relationship between periodontal disease and pregnancy complications", J Am Dent Assoc, 137(Suppl), pp.7S~13S (2006)
  57. Koh J, "MDSC subtypes and CD39 expression on CD8+T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC", Eur J Immunol, 50, pp.1810~1819 (2020)
  58. Mengos AE, "The CD14+HLA-DRlo", neg monocyte : an immunosuppressive phenotype that restrains responses to cancer immunotherapy, 2019, pp.10, 1147~
  59. Satoh Y, "Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy", Cancer Sci, 111, pp.2248~2258 (2020)
  60. Ostrand-Rosenberg S, "Myeloid derived-suppressor cells : their role in cancer and obesity", Curr Opin Immunol, 51, pp.68~75 (2018)
  61. Law AMK, "Myeloid-derived suppressor cells as a therapeutic target for cancer", Cells, 9, pp.9~ (2020)
  62. Kumar V, "The nature of myeloid-derived suppressor cells in the tumor microenvironment", Trends Immunol, 37, pp.208~220 (2016)
  63. Weber R, "IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy", Cell Immunol, 359, pp.104254~ (2021)
  64. Li S, "TET2 promotes antitumor immunity by governing G-MDSCs and CD8+T-cell numbers", EMBO Rep, 21, pp.e49425~ (2020)
  65. Zhang Q, "Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma", Cancer Discov, 11, pp.1248~1267 (2021)
  66. Sun R, "A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma : implications for the roles of MDSC and Th17 cells in lymphoma progression", Mol Oncol, 15, pp.246~261 (2021)
  67. Tavukçuoğlu E, "Human splenic polymorphonuclear myeloid-derived suppressor cells(PMN-MDSC)are strategically located immune regulatory cells in cancer", Eur J Immunol, 50, pp.2067~2074 (2020)
  68. Kawano M, "The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer", Sci Rep, 5, pp.18217~ (2015)
  69. Wang J, "Identification of CD4+CD25+CD127-regulatory T cells and CD14+HLADR-", low myeloidderived suppressor cells and their roles in the prognosis of breast cancer, 2016, pp.5, 208~212
  70. Tada K, "Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients", Cancer Immunol Res, 4, pp.592~599 (2016)
  71. Gunes EG, "The role of myeloid-derived suppressor cells in hematologic malignancies", Curr Opin Oncol, 32, pp.518~526 (2020)
  72. Shukla VC, "Reciprocal signaling between myeloid derived suppressor and tumor cells enhances cellular motility and is mediated by structural cues in the microenvironment", Adv Biosyst, 4, pp.e2000049~ (2020)
  73. Feng PH, "NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells", Cancer Immunol Immunother, 69, pp.2147~2155 (2020)
  74. Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
  75. Liu Z, "TLR 7", 8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages, 2020, pp.469, 173~185
  76. Karakasheva TA, "CD38+M-MDSC expansion characterizes a subset of advanced colorectal cancer patients", JCI Insight, 3, pp.e97022~ (2018)
  77. Kim J, "Tumor-associated macrophages and neutrophils in tumor microenvironment", Mediators Inflamm, 2016, pp.6058147~ (2016)
  78. Wang Y, "Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9", Adv Sci(Weinh), 6, pp.1901278~ (2019)
  79. Ye TH, "Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis", Cell Death Dis, 8, pp.e2534~ (2017)
  80. Lin Q, "The mechanism of the premetastatic niche facilitating colorectal cancer liver metastasis generated from myeloid-derived suppressor cells induced by the S1PR1-STAT3 signaling pathway", Cell Death Dis, 10, pp.693~ (2019)
  81. Long X, "Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity", Nat Microbiol, 4, pp.2319~2330 (2019)
  82. Sica A, "Origin and functions of tumor-associated myeloid cells(TAMCs)", Cancer Microenviron, 5, pp.133~149 (2012)
  83. Ibrahim ML, "Expression profiles and function of IL6in polymorphonuclear myeloid-derived suppressor cells", Cancer Immunol Immunother, 69, pp.2233~2245 (2020)
  84. Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
  85. Conway EM, "Macrophages, inflammation, and lung cancer", Am J Respir Crit Care Med, 193, pp.116~130 (2016)
  86. Milette S, "The innate immune architecture of lung tumors and its implication in disease progression", J Pathol, 247, pp.589~605 (2019)
  87. Adah D, "Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics", Pharmacol Res, 110, pp.25~34 (2016)
  88. Tavakkoli M, "A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer", Front Oncol, 9, pp.295~ (2019)
  89. Yang Z, "Myeloid-derived suppressor cells-new and exciting players in lung cancer", J Hematol Oncol, 13, pp.10~ (2020)
  90. Li YD, "Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer", Cancer Immunol Immunother, 68, pp.1501~1513 (2019)
  91. Mohrherr J, "JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression", Int J Cancer, 145, pp.3376~3388 (2019)
  92. Lee JW, "The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras", p53-driven lung cancer, 2019, pp.14, 1046~1060
  93. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
  94. Hori M, "Cancer incidence and incidence rates in Japan in 2009 : a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan(MCIJ)project", Jpn J Clin Oncol, 45, pp.884~891 (2015)
  95. Gatti-Mays ME, "If we build it they will come : targeting the immune response to breast cancer", NPJ Breast Cancer, 5, pp.37~ (2019)
  96. Duechler M, "The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes", Immunobiology, 219, pp.158~165 (2014)
  97. Ma X, "Myeloid-derived suppressor cells promote metastasis in breast cancer after the stress of operative removal of the primary cancer", Front Oncol, 9, pp.855~ (2019)
  98. Hoffmann SHL, "Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer", Theranostics, 9, pp.5869~5885 (2019)
  99. Safarzadeh E, "Circulating myeloid-derived suppressor cells : an independent prognostic factor in patients with breast cancer", J Cell Physiol, 234, pp.3515~3525 (2019)
  100. Hsu YL, "CXCL17-derived CD11b+Gr-1+myeloidderived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB", Breast Cancer Res, 21, pp.23~ (2019)
  101. Shou D, "Suppressive role of myeloid-derived suppressor cells(MDSCs)in the microenvironment of breast cancer and targeted immunotherapies", Oncotarget, 7, pp.64505~64511 (2016)
  102. Oh K, "A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 transsignaling in a murine model", Breast Cancer Res, 15, pp.R79~ (2013)
  103. Wang Z, "Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187", Oncogenesis, 9, pp.36~ (2020)
  104. Kumar S, "ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer", J Clin Invest, 128, pp.5095~5109 (2018)
  105. Brand A, "LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells", Cell Metab, 24, pp.657~671 (2016)
  106. Chang CH, "Metabolic competition in the tumor microenvironment is a driver of cancer progression", Cell, 162, pp.1229~1241 (2015)
  107. Li W, "Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triplenegative breast cancer", Cell Metab, 28, pp.87~103 (2018)
  108. Gaetani L, "CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases : implications for treatment", Trends Pharmacol Sci, 41, pp.1023~1037 (2020)
  109. González H, "Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases", J Neuroimmunol, 274, pp.1~13 (2014)
  110. Borisov KE, "The immunosuppressive microenvironment of malignant gliomas", Arkh Patol, 77, pp.54~63 (2015)
  111. Hosomi S, "Myeloid-derived suppressor cells infiltrate the brain and suppress neuroinflammation in a mouse model of focal traumatic brain injury", Neuroscience, 406, pp.457~466 (2019)
  112. Ranjan A, "Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth", Oncotarget, 8, pp.47632~47641 (2017)
  113. Haghayegh Jahromi N, "Intercellular adhesion molecule-1(ICAM-1)and ICAM-2 differentially contribute to peripheral activation and CNS entry of autoaggressive Th1 and Th17 cells in experimental autoimmune encephalomyelitis", Front Immunol, 10, pp.305~ (2020)
  114. Jin P, "Interferon-γand tumor necrosis factor-α polarize bone marrow stromal cells uniformly to a Th1 phenotype", Sci Rep, 6, pp.26345~ (2016)
  115. Pappalardo JL, "Transcriptomic and clonal characterization of T cells in the human central nervous system", Sci Immunol, 5, pp.eabb8786~ (2020)
  116. Knier B, "Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity", Nat Immunol, 19, pp.1341~1351 (2018)
  117. Melero-Jerez C, "Myeloid derived suppressor cells in inflammatory conditions of the central nervous system", Biochim Biophys Acta, 1862, pp.368~380 (2016)
  118. Melero-Jerez C, "The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis", Neurobiol Dis, 140, pp.104869~ (2020)
  119. Iacobaeus E, "Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis", Immunol Cell Biol, 96, pp.820~830 (2018)
  120. Melero-Jerez C, "The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis", Neurobiol Dis, 127, pp.13~31 (2019)
  121. Elliott DM, "Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells", Front Immunol, 9, pp.1782~ (2018)
  122. Mastorodemos V, "Cell-based modulation of autoimmune responses in multiple sclerosis and experimental autoimmmune encephalomyelitis : therapeutic implications", Neuroimmunomodulation, 22, pp.181~195 (2015)
  123. Moliné-Velázquez V, "The synthetic retinoid Am80 delays recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability", Neurobiol Dis, 67, pp.149~164 (2014)
  124. Moliné-Velázquez V, "Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis", Brain Pathol, 21, pp.678~691 (2011)
  125. Alabanza LM, "Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells", J Immunol, 191, pp.3764~3777 (2013)
  126. Mecha M, "2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs", Glia, 66, pp.1447~1463 (2018)
  127. Cantoni C, "Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis", Acta Neuropathol, 133, pp.61~77 (2017)
  128. Ioannou M, "Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease", J Immunol, 188, pp.1136~1146 (2012)
  129. Wegner A, "Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease", Immunology, 151, pp.26~42 (2017)
  130. Glenn JD, "Frontline Science : Induction of experimental autoimmune encephalomyelitis mobilizes Th17-promoting myeloid derived suppressor cells to the lung", J Leukoc Biol, 105, pp.829~841 (2019)
  131. Mi Y, "The emerging role of myeloid-derived suppressor cells in the glioma immune suppressive microenvironment", Front Immunol, 11, pp.737~ (2020)
  132. Vidyarthi A, "Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity", Cancer Immunol Immunother, 68, pp.1995~2004 (2019)
  133. Kamran N, "Immature myeloid cells in the tumor microenvironment : implications for immunotherapy", Clin Immunol, 189, pp.34~42 (2018)
  134. Arcuri C, "Microglia-glioma cross-talk: a two way approach to new strategies against glioma", Front Biosci(Landmark Ed), 22, pp.268~309 (2017)
  135. Gielen PR, "Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue", J Neuropathol Exp Neurol, 74, pp.390~400 (2015)
  136. Parney IF, "Basic concepts in glioma immunology", Adv Exp Med Biol, 746, pp.42~52 (2012)
  137. Wurdinger T, "Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells : how to break a vicious cycle", Biochim Biophys Acta, 1846, pp.560~575 (2014)
  138. Chai E, "LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression", Cancer Manag Res, 11, pp.7307~7315 (2019)
  139. Alban TJ, "Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis", JCI Insight, 3, pp.e122264~ (2018)
  140. Kohanbash G, "GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α", Cancer Res, 73, pp.6413~6423 (2013)
  141. Gielen PR, "Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8", 9 and arginase and suppress T cell function, 2016, pp.18, 1253~1264
  142. Gieryng A, "Immune microenvironment of gliomas", Lab Invest, 97, pp.498~518 (2017)
  143. Krishna U, "Uveitis : a sight-threatening disease which can impact all systems", Postgrad Med J, 93, pp.766~773 (2017)
  144. Mochizuki M, "A new era of uveitis : impact of polymerase chain reaction in intraocular inflammatory diseases", Jpn J Ophthalmol, 61, pp.1~20 (2017)
  145. Yang P, "Prevalence and clinical features of systemic diseases in Chinese patients with uveitis", Br J Ophthalmol, 105, pp.75~82 (2021)
  146. Kerr EC, "Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations", J Autoimmun, 31, pp.354~361 (2008)
  147. Jeong HJ, "Myeloid-derived suppressor cells mediate inflammation resolution in humans and mice with autoimmune uveoretinitis", J Immunol, 200, pp.1306~1315 (2018)
  148. Tu Z, "Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis", Invest Ophthalmol Vis Sci, 53, pp.959~966 (2012)
  149. Lee HJ, "Mesenchymal stem", stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells, 2015, pp.194, 3634~3645

관련 논문AI추천

Exploring the Potential of Glycolytic Modulation in Myeloid-Derived Suppressor Cells for Immunotherapy and Disease Management김지수, 민혜영, 최지연, 황광우대한면역학회 · Immune Network2024 · 제24권 제3호Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid LeukemiaAhn Ari, Bae Mi Hyun, Cho Young-Uk, Im Ho Joon, Jang Seongsoo, Kim Min-sun, Koh Kyung-Nam, Lee Je-Hwan, Lee Jung-Hee, Park Chan-Jeoung대한진단검사의학회 · Annals of Laboratory Medicine2021 · 제41권 제5호Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression김성협, 서은혜, 오충식, 이승현, 남궁지현대한면역학회 · Immune Network2018 · 제18권 제3호Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b＋Gr-1＋ Myeloid-derived Suppressor Cells강창율, 고현정, 김연정, 김윤선, 서정환, 이정미대한면역학회 · Immune Network2010 · 제10권 제3호면역세포와 암세포의 상호작용조선욱대한갑상선학회 · International Journal of Thyroidology2013 · 제6권 제2호The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets이흥규, Chae Won Kim, Kyun-Do Kim생화학분자생물학회 · BMB Reports2021 · 제54권 제1호

이 간행물의 다른 논문 (6건)

The Role of Upper Airway Microbiome in the Development of Adult Asthma김세훈, 장윤석, 최준표, 푸제pp. 1-18Toll-like Receptor 2 in Autoimmune InflammationReynolds Joseph M., Marks Kathryne E., Cho Kaylin, Stickling Courtneypp. 1-13Gut-Brain Connection: Microbiome, Gut Barrier, and Environmental Sensors장선영, 곽민규pp. 1-18Effect of Human or Mouse IL-7 on the Homeostasis of Porcine T Lymphocytes김지수, 박영호, 김선욱, 김상훈, 김현경, 정용우, 장준호, 최한별, 정강진, 박성필, 홍지화, 손려강, 강필용pp. 1-13Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy문지현, 이준형, 박효진, 하상준, 강태건pp. 1-16
원문 보기